Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Cellectis (NASDAQ:CLLS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Tectonic Therapeutic and Cellectis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
Profitability
This table compares Tectonic Therapeutic and Cellectis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| Cellectis | -234.39% | -74.55% | -22.65% |
Volatility & Risk
Tectonic Therapeutic has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500.
Valuation & Earnings
This table compares Tectonic Therapeutic and Cellectis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -8.17 |
| Cellectis | $9.19 million | 11.31 | -$101.06 million | ($1.30) | -1.44 |
Tectonic Therapeutic has higher earnings, but lower revenue than Cellectis. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectis beats Tectonic Therapeutic on 8 of the 14 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
